02096 News
SIMCERE PHARMA: Clinical Trials for SIM0610 Greenlit in China
SIMCERE PHARMA Enters Exclusive Licensing Deal with Ipsen, Potentially Worth Up to US$1.06 Billion
SIMCERE PHARMA's ENZESHU and ENDOSTAR Added to China's National Reimbursement Drug List
<Research>BOCOMI Releases November Recommended Chinese Stocks (Table)
<Study> UBS Ratings and Target Prices for Chinese Pharmaceuticals (Table)
<Research>BOCOMI: Trump's New Tariffs on Imported Innovative Medications Likely to Have Minimal Effect on Chinese Pharmaceutical Companies
SIMCERE PHARMA Plans to Generate HKD1.554B Net Through Top-up Placing at an 8% Discount
<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land
02096 Events
No data
02096 Monitor News
No data
02096 Earnings Analysis